Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis

Journal of Proteomics

Volumn 74, Issue 6, 2011, Pages 858-873

  Muto, Taika ^a,b   Taniguchi, Hirokazu ^c   Kushima, Ryoji ^c   Tsuda, Hitoshi ^c   Yonemori, Hirotaka ^a   Chen, Chen ^a   Sugihara, Yutaka ^a   Sakamoto, Kano ^a   Kobori, Yukiko ^a   Palmer, Helen ^a   Nakamura, Yukiko ^a,d   Tomonaga, Takeshi ^d   Tanaka, Hiroshi ^b   Mizushima, Hiroshi ^b   Fujita, Shin ^c   Kondo, Tadashi ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEOME;

ADULT; ALKALINITY; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOELECTRIC FOCUSING; ISOELECTRIC POINT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

COLORECTAL NEOPLASMS; FEMALE; HUMANS; ISOELECTRIC POINT; MALE; MIDDLE AGED; NEOPLASM PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 79955469684     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2011.02.030     Document Type: Article

References (90)

1. Weitz J., Koch M., Debus J., Hohler T., Galle P.R., Buchler M.W. Colorectal cancer. Lancet 2005, 365:153-165.
2. Pfister D.G., Benson A.B., Somerfield M.R. Clinical practice. Surveillance strategies after curative treatment of colorectal cancer. N Engl J Med 2004, 350:2375-2382.
3. Liefers G.J., Tollenaar R.A. Cancer genetics and their application to individualised medicine. Eur J Cancer 2002, 38:872-879.
4. Popa-Velea O., Cernat B., Tambu A. Influence of personalized therapeutic approach on quality of life and psychiatric comorbidity in patients with advanced colonic cancer requiring palliative care. J Med Life 2010, 3:343-347.
5. Barderas R., Babel I., Casal J.I. Colorectal cancer proteomics, molecular characterization and biomarker discovery. Proteomics Clin Appl 2010, 4:159-178.
6. Bitarte N., Bandres E., Zarate R., Ramirez N., Garcia-Foncillas J. Moving forward in colorectal cancer research, what proteomics has to tell. World J Gastroenterol 2007, 13:5813-5821.
7. Nibbe R.K., Koyuturk M., Chance M.R. An integrative -omics approach to identify functional sub-networks in human colorectal cancer. PLoS Comput Biol 2010, 6:e1000639.
8. Alfonso P., Canamero M., Fernandez-Carbonie F., Nunez A., Casal J.I. Proteome analysis of membrane fractions in colorectal carcinomas by using 2D-DIGE saturation labeling. J Proteome Res 2008, 7:4247-4255.
9. Ma Y., Zhao M., Zhong J., Shi L., Luo Q., Liu J., et al. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem 2010, 110:1512-1519.
10. Ang C.S., Nice E.C. Targeted in-gel MRM: a hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res 2010, 9:4346-4355.
11. Chen J.S., Chen K.T., Fan C.W., Han C.L., Chen Y.J., Yu J.S., et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel-assisted digestion and iTRAQ labeling mass spectrometry. FEBS J 2010, 277:3028-3038.
12. Xie L.Q., Zhao C., Cai S.J., Xu Y., Huang L.Y., Bian J.S., et al. Novel proteomic strategy reveal combined alpha1 antitrypsin and cathepsin D as biomarkers for colorectal cancer early screening. J Proteome Res 2010, 9:4701-4709.
13. Pedersen J.W., Blixt O., Bennett E.P., Tarp M.A., Dar I., Mandel U., et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011, 128:1860-1871.
14. Spisak S., Galamb B., Sipos F., Galamb O., Wichmann B., Solymosi N., et al. Applicability of antibody and mRNA expression microarrays for identifying diagnostic and progression markers of early and late stage colorectal cancer. Dis Markers 2010, 28:1-14.
15. Morishita A., Gong J., Nomura T., Yoshida H., Izuishi K., Suzuki Y., et al. The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int J Oncol 2010, 37:829-835.
16. Kondo T., Hirohashi S. Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 2007, 1:2940-2956.
17. Kinzkofer-Peresch A., Patestos N.P., Fauth M., Kogel F., Zok R., Radola B.J. Native protein blotting after isoelectric focusing in fabric reinforced polyacrylamide gels in carrier ampholyte generated or immobilized pH gradients. Electrophoresis 1988, 9:497-511.
18. Cowdrey G., Gould B., Rees J., Firth G. The separation and detection of alkaline oligoclonal IgG bands in cerebrospinal fluid using immobilised pH gradients. Electrophoresis 1990, 11:813-818.
19. Orimo T., Ojima H., Hiraoka N., Saito S., Kosuge T., Kakisaka T., et al. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology 2008, 48:1851-1863.
20. Suehara Y., Kondo T., Seki K., Shibata T., Fujii K., Gotoh M., et al. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 2008, 14:1707-1717.
21. Yamada M., Fujii K., Koyama K., Hirohashi S., Kondo T. The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis. J Proteomics Bioinform 2009, 02:1-18.
22. Uemura N., Nakanishi Y., Kato H., Saito S., Nagino M., Hirohashi S., et al. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer 2009, 124:2106-2115.
23. Lundberg E., Uhlen M. Creation of an antibody-based subcellular protein atlas. Proteomics 2010, 10:3984-3996.
24. Picotti P., Rinner O., Stallmach R., Dautel F., Farrah T., Domon B., et al. High-throughput generation of selected reaction-monitoring assays for proteins and proteomes. Nat Methods 2010, 7:43-46.
25. Charpin C., Secq V., Giusiano S., Carpentier S., Andrac L., Lavaut M.N., et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 2009, 124:2124-2134.
26. Cui Y., Wu J., Zong M., Song G., Jia Q., Jiang J., et al. Proteomic profiling in pancreatic cancer with and without lymph node metastasis. Int J Cancer 2009, 1:1614-1621.
27. Kobayashi H., Sagara J., Kurita H., Morifuji M., Ohishi M., Kurashina K., et al. Clinical significance of cellular distribution of moesin in patients with oral squamous cell carcinoma. Clin Cancer Res 2004, 10:572-580.
28. Jimenez C.R., Knol J.C., Meijer G.A., Fijneman R.J. Proteomics of colorectal cancer: overview of discovery studies and identification of commonly identified cancer-associated proteins and candidate CRC serum markers. J Proteomics 2010, 73:1873-1895.
29. Bi X., Lin Q., Foo T.W., Joshi S., You T., Shen H.M., et al. Proteomic analysis of colorectal cancer reveals alterations in metabolic pathways: mechanism of tumorigenesis. Mol Cell Proteomics 2006, 5:1119-1130.
30. Kim H.J., Kang H.J., Lee H., Lee S.T., Yu M.H., Kim H., et al. Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 2009, 8:1368-1379.
31. Li M., Zhai Q., Bharadwaj U., Wang H., Li F., Fisher W.E., et al. Cyclophilin A is overexpressed in human pancreatic cancer cells and stimulates cell proliferation through CD147. Cancer 2006, 106:2284-2294.
32. Kim H., Kang H.J., You K.T., Kim S.H., Lee K.Y., Kim T.I., et al. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006, 6:3466-3476.
33. Christofk H.R., Vander Heiden M.G., Harris M.H., Ramanathan A., Gerszten R.E., Wei R. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008, 452:230-234.
34. Thierolf M., Hagmann M.L., Pfeffer M., Berntenis N., Wild N., Roeßler M., et al. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin Appl 2008, 2:11-22.
35. Zhao L., Wang H., Sun X., Ding Y. Comparative proteomic analysis identifies proteins associated with the development and progression of colorectal carcinoma. FEBS J 2010, 20:4195-4204.
36. Roessler M., Rollinger W., Palme S., Hagmann M.L., Berndt P., Engel A.M., et al. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer. Clin Cancer Res 2005, 11:6550-6557.
37. Langbein S., Zerilli M., Hausen A., Staiger W., Rensch-Boschert K., Lukan N., et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006, 94:578-585.
38. Li X.M., Patel B.B., Blagoi E.L., Patterson M.D., Seeholzer S.H., Zhang T., et al. Analyzing alkaline proteins in human colon crypt proteome. J Proteome Res 2004, 3:821-833.
39. Gaber A., Nodin B., Hotakainen K., Nilsson1 E., Stenman U.F., Bjartell A., et al. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer 2010, 10:498.
40. Soreide K., Janssen E.A., Korner H., Baak J.P.A. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol 2006, 209:147-156.
41. Hoffmann P., Ji H., Moritz R.L., Connolly L.M., Frecklington D.F., Layton M.J., et al. Continuous free-flow electrophoresis separation of cytosolic proteins from the human colon carcinoma cell line LIM 1215: a non two-dimensional gel electrophoresis-based proteome analysis strategy. Proteomics 2001, 1:807-818.
42. Duncan R., Carpenter B., Main L.C., Telfer C., Murray G.I. Characterisation and protein expression profiling of annexins in colorectal cancer. Br J Cancer 2008, 98:426-433.
43. Song J., Shih I.M., Chan D.W., Zhang Z. Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. Neoplasia 2009, 11:605-614.
44. Chang H.J., Lee M.R., Hong S.H., Yoo B.C., Shin Y.K., Jeong J.Y., et al. Identification of mitochondrial FoF1-ATP synthase involved in liver metastasis of colorectal cancer. Cancer Sci 2007, 98:1184-1191.
45. -) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer. Cancer Genet Cytogenet 2010, 196:45-55.
46. Patel B.B., Li X.M., Dixon M.P., Blagoi E.L., Seeholzer S.H., Chen Y., et al. Searchable high-resolution 2D gel proteome of the human colon crypt. J Proteome Res 2007, 6:2232-2238.
47. Pollard P.J., Wortham N.C., Tomlinson I.P. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase. Ann Med 2003, 35:632-639.
48. Guirons J.S., Zeqiraj E., Schumacher U., Greenwell P., Dwek M. Proteome analysis of metastatic colorectal cancer cells recognized by the lectin Helix pomatia agglutinin (HPA). Proteomics 2007, 7:4082-4089.
49. He Z.Y., Wen H., Shi C.B., Wang J. Up-regulation of hnRNP A1, ezrin, tubulin β-2C and annexin A1 in sentinel lymph nodes of colorectal cancer. World Gastoroenterol 2010, 16:4670-4676.
50. Volmer M.W., Stuhler K., Zapatka M., Schoneck A., Klein-Scory S., Schmiegel W., et al. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005, 5:2587-2601.
51. Kim J., Kim S.H., Lee S.U., Ha1 G.H., Kang D.G., Ha1 N.Y., et al. Proteome analysis of human liver tumor tissue by two-dimensional gel electrophoresis and matrixassisted laser desorption/ionization-mass spectrometry for identification of disease-related proteins. Electrophoresis 2002, 23:4142-4156.
52. Gourley G.R., Yang L., Higgins L.A., Riviere M.A., David L.L. Proteomic analysis of biopsied human colonic mucosa. J Pediatr Gastroenterol Nutr 2010, 51:46-54.
53. Okano T., Kondo T., Kakisaka T., Fujii K., Yamada M., Kato H., et al. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics 2006, 6:3938-3948.
54. Yang S.B., Chen X., Wu B.Y., Wang M.W., Cai C.H., Cho D.B., et al. Immunoglobulin kappa and immunoglobulin lambda are required for expression of the anti-apoptotic molecule Bcl-xL in human colorectal cancer tissue. Scand J Gastroenterol 2009, 44:1443-1451.
55. Schnier J.B., Nishi K., Gumerlock P.H., Gorin F.A., Bradbury E.M. Glycogen synthesis correlates with androgen-dependent growth arrest in prostate cancer. BMC Urol 2005, 5:6.
56. Charafe-Jauffret E., Monville F., Bertucci F., Esterni B., Ginestier C., Finetti P., et al. Moesin expression is a marker of basal breast carcinomas. Int J Cancer 2007, 121:1779-1785.
57. Belbin T.J., Singh B., Smith R.V., Socci N.D., Wreesmann V.B. Molecular profiling of tumor progression in head and neck cancer. Arch Otolaryngol Head Neck Surg 2005, 131:10-18.
58. Kobel M., Gradhand E., Zeng K., Schmitt W.D., Kriese K., Lantzsch T. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol 2006, 25:121-130.
59. Bartholow T.L., Chandran U.R., Becich M.J., Parwani A.V. Immunohistochemical staining of radixin and moesin in prostatic adenocarcinoma. BMC Clin Pathol 2011, 11:1.
60. Cai X.W., Shedden K., Ao X., Davis M., Fu X.L., Lawrence T.S., et al. Plasma proteomics analysis may identify new markers for radiation-induced lung toxicity patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2010, 77:867-876.
61. Harermann J.K., Roblick U.J., Luke B.T., Prieto D.A., Finlay W.J.J., Podust V.N. Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. Gastroenterol 2006, 131:1020-1029.
62. Kasapovic J., Pejic S., Stojiljkovic V., Todorovicv A., Radosevic-Jelic L., Saicic Z.S., et al. Antioxidant status and lipid peroxidation in the blood of breast cancer patients of different ages after chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide. Clin Biochem 2010, 43:1287-1293.
63. Roncucci L., Mora E., Mariani F. Myeloperoxidase-positive cell infiltration in colorectal carcinogenesis as indicator of colorectal cancer risk. Cancer Epidemiol Biomark 2008, 17:2291-2297.
64. Willis N.D., Cox1 T.R., Rahman-Casans S.F., Smits K., Przyborski S.A., Brandt P. Lamin A/C is a risk biomarker in colorectal cancer. PLoS ONE 2008, 3:e2988.
65. Yuan Y., Li W., Li L., Yang X., Gu R., Liu H., et al. Effects of tetrazanbigen on the protein expression in human hepatocellular carcinoma cell line QGY-7701. J Huazhong Univ Sci Technolog Med Sci 2009, 29:304-308.
66. Lam J.S., Seligson D.B., Yu H., Li A., Eeva M., Pantuck A.J., et al. Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score. BJU Int 2006, 98:445-451.
67. Kucherlapati M., Yang K., Kuraguchi M., Zhao J., Lia M., Heyer J. Haploinsufficiency of flap endonuclease (fen1) leads to rapid tumor progression. Proc Natl Acad Sci USA 2002, 99:9924-9929.
68. Mikuriya K., Kuramatsu Y., Ryozawa S., Fujimoto M., Mori S., Oka M., et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007, 30:849-855.
69. Hirakawa H., Shibata K., Nakayama T. Localization of cortactin is associated with colorectal cancer development. Int J Oncol 2009, 35:1271-1276.
70. Otsubo T., Iwaya K., Mukai Y., Mizokami Y., Serizawa H., Matsuoka T., et al. Involvement of Arp2/3 complex in the process of colorectal carcinogenesis. Mod Pathol 2004, 17:461-467.
71. Tomonaga T., Matsushita K., Yamaguchi S., Oh-Ishi M., Kodera Y., Maeda T. Identification of altered protein expression and post-translational modifications in primary colorectal cancer by using agarose two-dimensional gel electrophoresis. Clin Cancer Res 2004, 10:2007-2014.
72. Kranosov G.S., Oparina N.Y., Hankin S.L., Mashkova T.D., Ershov A.N., Zataepina O.G., et al. Identification of proteins with altered expression in colorectal cancer by means of 2D-proteomics. Mol Biol 2009, 43:321-328.
73. Chen G., Gharib T.G., Huang C.C., Thomas D.G., Shedden K.A., Taylor J.M., et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res 2002, 8:2298-2305.
74. Nibbe R.K., Markowitz S., Myeroff L., Ewing R., Chance M.R. Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. Mol Cell Proteomics 2009, 8:827-845.
75. Tanaka H., Tsukamoto T., Mizoshita T., Inada K., Ogasawara N., Cao X., et al. Expression of small intestinal and colonic phenotypes in complete intestinal metaplasia of the human stomach. Virchows Arch 2005, 447:806-815.
76. Kummola L., Hamalainen J.M., Kivela J., Kivela A.J., Saarnio J., Karttunen T. Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 2005, 5:41.
77. Mizoshita T., Tsukamoto T., Tanaka H., Takenaka Y., Kato S., Cao X., et al. Colonic and small-intestinal phenotypes in gastric cancers: relationships with clinicopathological findings. Pathol Int 2005, 10:611-618.
78. Kang B., Hao C., Wang H., Zhang J., Xing R., Shao J., et al. Evaluation of hepatic-metastasis risk of colorectal cancer upon the protein signature of PI3K/AKT pathway. J Proteome Res 2008, 7:3507-3515.
79. Alfonso P., Nunez A., Gurpide J.M., Lombardia L., Sanchez L., Casal J.I. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics 2005, 5:2602-2611.
80. Cappello F., David S., Rappa F., Bucchieri F., Marasa L., Bartolotta T.E. The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer 2005, 5:139.
81. Krasnov G.S., Khankin S.L., Bukurova Y.A., Zatsepina O.G., Oparina N.Y., Garbuz D.G., et al. Proteomic expression analysis of human colorectal cancer: of soluble overexpressed proteins. Mol Biol 2009, 43:562-566.
82. Rho J.R., Roehrl M.H.A., Wang J.Y. Tissue proteomics reveals differential and compartment-specific expression of the homologs transgelin and transgelin-2 in lung adenocarcinoma and its stroma. J Proteome Res 2009, 8:5610-5618.
83. Zhou J., Mulshine J.L., Ro J.Y., Avis I., Yu R., Lee J.J., et al. Expression of heterogeneous nuclear ribonucleoprotein A2/B1 in bronchial epithelium of chronic smokers. Clin Cancer Res 1998, 4:1631-1640.
84. Lee C., Lum J.H., Cheung B.P., Wong M., Butt Y.K., Tam M.F., et al. Identification of the heterogeneous nuclear ribonucleoprotein A2/B1 as the antigen for the gastrointestinal cancer specific monoclonal antibody MG7. Proteomics 2005, 5:1160-1166.
85. Sanders Y.Y., Hammons G.J., Lyn-Cook B.D. Increased expression of heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP) in pancreatic tissue from smokers and pancreatic tumor cells. Cancer Lett 2002, 183:215-220.
86. Ma Y., Peng J., Liu W., Zhang P., Huang L., Gao B. Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics 2009, 8:1878-1890.
87. Yeo M., Park H.J., Kim D.K., Kim Y.B., Cheong J.Y., Lee K.J., et al. Loss of SM22 is a characteristic signature of colon carcinogenesis and its restoration suppresses colon tumorigenicity in vivo and in vitro. Cancer 2010, 116:2581-2589.
88. Friedman D.B., Hill S., Keller J.W., Merchant N.B., Levy S.E., Coffey R.J., et al. Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 2004, 4:793-811.
89. Loignon M., Miao W., Hu L., Bier A., Bismar T.A., Scrivens P.J., et al. Cul3 overexpression depletes Nrf2 in breast cancer and is associated with sensitivity to carcinogens, to oxidative stress, and to chemotherapy. Mol Can Ther 2009, 8:2432-2440.
90. Lai C.C., You J.F., Yeh C.Y., Chen J.S., Tang R., Wan J.Y., et al. Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Colorectal Dis 2011, 26:473-481.